Additionally, two NGS-based tests have recently achieved FDA approval: the Guardant360® CDx from Guardant Health to determine EGFR status in NSCLC patients and the FoundationOne® Liquid CDx from Foundation medicine for NSCLC, metastatic castrate resistant prostate cancer (mCRPC), ovarian and breast cancer patients before administration of TKI, PIK3CA, or poly(ADP-ribose) polymerase 1 (PARP) inhibitors [48]. Here, PARP1 is linked to breast cancer.